Company intelligence / Profile preview

Wuhan YZY Biopharma Co., Ltd.

Ownership: Private
Employees: ~114
Development stage: Phase 2

Overview

The company's core product M701 is in Phase III/pivotal trial for malignant ascites with BLA submission expected in Q1 2025. Several other candidates are in Phase I and Phase II trials.

Therapeutic areas: OphthalmologyOncologyInfectious DiseasesHematology
Modalities: Bispecific antibodiesRecombinant proteinsVaccines
Industry: Biotech

Drug pipeline

8 assets

M701

7 more assets in the full pipeline.

Request access →

Partnerships

Wuhan Institute of VirologyShenzhen Kangzhe VisionSOTER BIOPHARMACMS Vision

Beyond the preview

Go deeper on Wuhan YZY Biopharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan YZY Biopharma Co., Ltd..

Explore the full profile